
Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
131 articles by Michael Gibney
-
How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times
Nov. 30, 2023 -
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Nov. 28, 2023 -
Organon’s chief medical officer wants to change how the world sees women’s health
Nov. 22, 2023 -
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Nov. 16, 2023 -
A biotech tackles drug discovery with transcription factor know-how
Nov. 15, 2023 -
How pharma leaders talk about ethics in a highly criticized industry
Nov. 9, 2023 -
The thorniest questions facing pharma, according to a leading bioethicist
Nov. 6, 2023 -
How Big Pharma keeps the oncology engines hot with a host of strategies
Nov. 2, 2023 -
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
Oct. 31, 2023 -
Red Jacket: Dr. Jeremy Levin, a transformational leader
Oct. 27, 2023 -
Pfizer’s new shot approval adds to a growing vaccine prowess
Oct. 24, 2023 -
Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
Oct. 19, 2023 -
PharmaVoice 100s: Rare disease warriors
Oct. 16, 2023 -
Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future
Oct. 12, 2023 -
FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO
Oct. 5, 2023 -
PharmaVoice 100s: Cancer care visionaries
Oct. 2, 2023 -
The PharmaVoice 100: Trailblazers
Sept. 29, 2023 -
Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk
Sept. 28, 2023 -
Do humans have a place in pharma’s AI future?
Sept. 26, 2023 -
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Sept. 21, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Sept. 15, 2023 -
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Sept. 14, 2023 -
‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Sept. 7, 2023 -
Finding the right flu vaccine is hard. Getting people to take it is harder.
Aug. 30, 2023 -
‘We need to do better:’ A biotech CEO on standing apart from the crowd
Aug. 29, 2023